Biological
Rhinovirus
Rhinovirus is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph not_applicable
3
75%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (25.0%)
N/A3 (75.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
unknownnot_applicable
Virus and Bronchial Epithelium in Children and the Elderly
NCT06224062
completedphase_2
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
NCT02660489
completednot_applicable
Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
NCT02111772
completednot_applicable
Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
NCT01669603
Clinical Trials (4)
Showing 4 of 4 trials
NCT06224062Not Applicable
Virus and Bronchial Epithelium in Children and the Elderly
NCT02660489Phase 2
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
NCT02111772Not Applicable
Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
NCT01669603Not Applicable
Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4